Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Next Previous
Trial Profile

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary) ; Aflibercept
  • Indications Diabetes mellitus; Diabetic macular oedema
  • Focus Adverse reactions
  • Acronyms HULK
  • Sponsors Clearside Biomedical

    • Most Recent Events

    • 13 Nov 2017 Results presented in a Clearside Biomedical media release.
    • 13 Nov 2017 According to a Clearside Biomedical media release, preliminary results were presented during the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.
    • 08 Nov 2017 According to a Clearside Biomedical media release, the company expects to report preliminary results from the trial on November 10th at the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top